HDAC10 Is Positively Associated With PD-L1 Expression and Poor Prognosis in Patients With NSCLC

被引:19
|
作者
Liu, Xiaomei [1 ]
Wang, Yuxi [2 ]
Zhang, Rong [3 ]
Jin, Ting [1 ]
Qu, Liangliang [1 ]
Jin, Qianwen [2 ]
Zheng, Jiasu [2 ]
Sun, Jiaqi [2 ]
Wu, Ziqing [2 ]
Wang, Linxi [2 ]
Liu, Tianxu [2 ]
Zhang, Yinxu [4 ]
Meng, Xiao [1 ]
Wang, Ying [1 ]
Wei, Ning [5 ,6 ]
机构
[1] Jinzhou Med Univ, Dept Oncol, Affiliated Hosp 1, Jinzhou, Peoples R China
[2] Jinzhou Med Univ, Dept Med, Jinzhou, Peoples R China
[3] Dalian Hosp Tradit Chinese Med, Pharm Dept, Daliang, Peoples R China
[4] Jinzhou Med Univ, Affiliated Hosp 1, Dept Surg, Jinzhou, Peoples R China
[5] Univ Pittsburgh, Sch Med, Dept Med, Div Hematol Oncol, Pittsburgh, PA 15213 USA
[6] Univ Pittsburgh, UPMC Hillman Canc Ctr, Canc Therapeut Program, Pittsburgh, PA 15260 USA
来源
FRONTIERS IN ONCOLOGY | 2020年 / 10卷
关键词
NSCLC; HDAC10; PD-L1; pulmonary squamous carcinoma; adenocarcinoma; HISTONE DEACETYLASE; LUNG-CANCER; INHIBITION; TARGET;
D O I
10.3389/fonc.2020.00485
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Currently, non-small cell lung carcinoma (NSCLC) is a major worldwide health problem. Meanwhile accumulating evidence indicates that histone deacetylase (HDAC) activation could induce PD-L1 expression in various types of cancer, especially in myeloma and B-cell lymphomas. Therefore, we hypothesized that high-level expression of HDAC10 is associated with PD-L1 induction and poor prognosis in patients with NSCLC. In total 180 NSCLC patients receiving complete pulmonary resection and systematic lymph node dissection were enrolled from April 2004 to August 2009. The patients with integrated clinicopathological records were followed up. The expression level of HDAC10 and PD-L1 in tissue samples was determined by immunohistochemistry. We observed that HDAC10 expression in lung cancer tissue is significantly higher than that in corresponding para-cancer tissue. Moreover, HDAC10 expression positively correlated with the expression level of PD-L1 (r = 0.213, P < 0.05) in NSCLC patients. Subgroup, multivariate analysis showed that the expression level of HDAC10 can be an independent prognostic factor and high-level expression of HDAC10 indicated poor overall survival for pulmonary carcinoma (r = 0.540, P < 0.001). Our findings suggest that the expression level of HDAC10 is positively associated with PD-L1 expression and may predict the outcome of patients with NSCLC.
引用
收藏
页数:7
相关论文
共 50 条
  • [1] High-level expression of HDAC10 is associated with PD-L1 expression and poor prognosis in patients with non-small cell lung cancer receiving pulmonectomy
    Liu, X.
    [J]. ANNALS OF ONCOLOGY, 2019, 30
  • [2] PD-L1 Expression is Associated With Poor Prognosis in Renal Cell Carcinoma
    Carlsson, Jessica
    Sundqvist, Pernilla
    Kosuta, Vezira
    Falt, Anna
    Giunchi, Francesca
    Fiorentino, Michelangelo
    Davidsson, Sabina
    [J]. APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY, 2020, 28 (03) : 213 - 220
  • [3] PD-L1 expression is common and indicates poor prognosis
    Clemens Thoma
    [J]. Nature Reviews Urology, 2016, 13 (1) : 5 - 5
  • [4] High PD-L1 expression was associated with poor prognosis in 870 Chinese patients with breast cancer
    Qin, Tao
    Zeng, Yin-duo
    Qin, Ge
    Xu, Fei
    Lu, Jia-bin
    Fang, Wen-feng
    Xue, Cong
    Zhan, Jian-hua
    Zhang, Xin-ke
    Zheng, Qiu-fan
    Peng, Rou-jun
    Yuan, Zhong-yu
    Zhang, Li
    Wang, Shu-sen
    [J]. ONCOTARGET, 2015, 6 (32) : 33972 - 33981
  • [5] PD-L1 tumor expression is associated with poor prognosis and systemic immunosuppression in glioblastoma
    Noronha, Carolina
    Ribeiro, Ana Sofia
    Taipa, Ricardo
    Leitao, Dina
    Schmitt, Fernando
    Reis, Joaquim
    Faria, Claudia
    Paredes, Joana
    [J]. JOURNAL OF NEURO-ONCOLOGY, 2022, 156 (03) : 453 - 464
  • [6] PD-L1 tumor expression is associated with poor prognosis and systemic immunosuppression in glioblastoma
    Carolina Noronha
    Ana Sofia Ribeiro
    Ricardo Taipa
    Dina Leitão
    Fernando Schmitt
    Joaquim Reis
    Cláudia Faria
    Joana Paredes
    [J]. Journal of Neuro-Oncology, 2022, 156 : 453 - 464
  • [7] PD-L1 expression in NSCLC
    Janzic, U.
    Kern, I.
    Janzic, A.
    Cavka, L.
    Cufer, T.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (04) : S58 - S59
  • [8] Overexpression of PD-L1 and PD-L2 Is Associated with Poor Prognosis in Patients with Hepatocellular Carcinoma
    Jung, Hae Il
    Jeong, Dongjun
    Ji, Sanghee
    Ahn, Tae Sung
    Bae, Sang Ho
    Chin, Susie
    Chung, Jun Chul
    Kim, Hyung Chul
    Lee, Moon Soo
    Baek, Moo-Jun
    [J]. CANCER RESEARCH AND TREATMENT, 2017, 49 (01): : 246 - 254
  • [9] PD-L1 Expression Predicts Prognosis in Completely Resected NSCLC Patients with an EGFR Mutation
    Qi, Y. F.
    Qiu, Z. B.
    Wu, Y. L.
    Zhong, W. Z.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S204 - S205
  • [10] Expression of PD-L1 is associated with poor prognosis in breast cancer: A meta-analysis
    Zhang, M.
    [J]. ANNALS OF ONCOLOGY, 2016, 27